# UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus

> **NCT02192775** · PHASE2 · COMPLETED · sponsor: **University of Arkansas** · enrollment: 2 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** MV-NIS

## Key facts

- **NCT ID:** NCT02192775
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2019-08-20
- **Final completion:** 2019-08-20
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02192775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02192775, "UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02192775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*